The breadth and depth of data across multiple leukemia subtypes and settings strengthen revumenib's competitive position as a first-in-class menin inhibitor. Traders should watch for updates on the ongoing pivotal frontline combination trials, which could drive further upside if results confirm these early signals.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $17.91entry
- T+1 · 5mo ago +1.90%α +1.36% · $18.25
- T+5 · 5mo ago +6.31%α +5.88% · $19.04
- T+20 · 4mo ago +38.69%α +36.80% · $24.84
- T+60 · 2mo ago +14.80%α +10.40% · $20.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar patients, a Phase 1 frontline combo trial with 97% CRc, and the SAVE trial with 88% ORR. The data reinforce revumenib's broad activity across multiple acute leukemia subtypes and settings, supporting its commercial potential and ongoing pivotal trials.
Key Facts
- Real-world ROAR study: 82% ORR (9/11) and 64% CR/CRh (7/11) in R/R NPM1m or KMT2Ar acute leukemia.
- Phase 1 frontline combo: 97% CRc (34/35) and 86% MRD negativity (25/29) in newly diagnosed NPM1m/KMT2Ar AML.
- SAVE trial (R/R): 88% ORR (37/42), 68% MRD negativity (25/37) among responders, 45% transplant rate (19/42).
- Post-hoc AUGMENT-101: 95% estimated 12-month OS in patients resuming revumenib post-HSCT.
- NUP98r data: 28% ORR (7/25) in heavily pretreated patients with poor-prognosis subtype.
- Safety consistent with established profile; no new safety signals across studies.
Financial Impact
No financial figures provided; data supports revumenib's potential label expansion and market penetration in acute leukemia, a multi-billion-dollar market.
Risk Factors
- Competition from other menin inhibitors in development (e.g., Kura Oncology's ziftomenib).
- Regulatory risks for label expansion; pivotal trial results may differ from early-phase data.
- Commercial execution risk; revumenib is recently approved and market adoption is still ramping.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310342 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Viewing Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers